It is estimated that pancreatic cancer will be the 2 nd leading cause of cancer-related deaths globally by 2030, highlighting the ongoing lack of effective treatment options in this devastating condition. There is a lack of reliable prognostic or predictive markers in pancreatic cancer to guide management decisions, whether for systemic chemotherapy, molecularly targeted therapies, or immunotherapies.
Introduction
Pancreatic cancer currently has the lowest survival rate of all cancers. Only 3 out of every 100 patients diagnosed with pancreatic cancer survives beyond 5 years (1) . Recent published data looking at outcomes from 2005-2015 demonstrate no improvements in survival outcomes in the last 10 years (2) . Pancreatic cancer is currently the 5 th most common cause of cancer related death in the United
States, but is projected by 2030, to become the 2 nd leading cause of cancer related death globally (3).
These statistics highlight the need for not only better therapies but also more durable treatment responses.
The most common form of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). PDACs are stromal-rich tumours that develop within the exocrine compartment of the pancreatic gland. PDAC accounts for more than 85% of all pancreatic malignancies (4) . Early stage or resectable disease occurs in just 20% of cases, 35-40% have locally advanced unresectable disease and 45-55% have metastatic disease at presentation (3) . Factors contributing to more advanced stage at diagnosis include the nonspecific nature of the presenting symptoms, the lack of good biomarkers to identify patients at risk of the disease, and the retroperitoneal location of the pancreas which limits routine tissue sampling and radiographic screening.
A unifying feature of all pancreatic tumours is the presence of immune and fibroblast cells, suggesting a critical role for inflammation in tumour progression. The impermeable desmoplastic stroma found around the pancreatic tumour is hypothesised to prevent immune cell infiltration and hinder effective delivery of chemotherapy (5, 6) . It has also been suggested that abnormal stromal activation contributes to tumorigenesis, and further immunosuppression, hypoxia and an anti-angiogenic tumour microenvironment (5) . One proposed model suggests that PDAC evolution occurs from PanIN 1 through to PanIN3 and then to invasive PDAC with progressive accumulation of desmoplastic stroma and modulation of the character of leucocyte infiltration altering through this process (7). Tumour associated macrophages (TAM) are reported to increase early in PDAC tumorigenesis, with reduction or varying levels of neutrophils and T cells present in PanIN and PDAC (8) .
Genomic alterations are also implicated in the development of PDAC and may play a role in the immunogenicity of individual tumours. The most commonly occurring mutations in PDAC include KRAS in 90%; TP53 in 50-80%, and CDKN2A in 5-10% of PDAC tumours (8) . PDAC typically has a relatively low mutation burden at 3-4/MB which my in-part account for the poor antigenicity and general lack of response to immunotherapy (9, 10) . Six immune subtypes have been identified across a range of solid tumours -immunologically quiet, lymphocyte deplete, inflammatory, wound healing, IFN dominant, and TGF dominant (11) . These subtypes appear to be governed by variations in immune cells -namely macrophages and lymphocytes signatures, Th1:Th2 cell ratio, tumour heterogeneity and genomic based differences of aneuploidy, neo-antigen load, cell proliferation, and expression of immunomodulatory genes (11, 12) . A correlation between specific mutations and leucocyte levels has also been described across a range of tumour types, such that mutations in BRAF, TP53 or CASP8 relate to increased leucocyte levels while mutations in CTNNB1, NRAS and IDH1 are associated with decreased leucocyte levels in some tumours (11) .
Other contributing factors that influence tumour-immune interactions in this complex intracellular and extracellular messaging network include differences in copy number, epigenetic changes, microRNAs and transcription (11, 12) . More specifically for PDAC tumours, genomic immune analysis has identified a predominantly inflammatory immune signature that is defined by raised levels of TH17
and Th1 genes, as well as a low to moderate tumour cell proliferation (11) . Not surprisingly, a low leucocyte proportion of tumour stromal fraction of <10% was reported.
Current treatment Paradigm
Pancreatectomy remains the single most effective treatment modality for the management of early stage disease, and the only potential for cure (13) . However, even with "curative" resection and adjuvant therapy, the 5-year survival rate of early stage resected PDAC remains limited to 20-25% (14) . For patients with advanced disease at presentation, the outlook is even more dismal with systemic therapy offering only a modest benefit (15) . The use of single agent gemcitabine chemotherapy achieves survival rates of only 27-23% at 1 year and 2% at 5 years (15) . The median survival with locally advanced disease ranges from 9 to 15 months, whilst for those with metastatic disease is as low as 3-6 months (3, 4).
In recent years, the use of two combination chemotherapy regimens have demonstrated superior efficacy over single agent gemcitabine. The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan and 5 fluorouracil) in the advanced PDAC setting extended the median OS to 11 months, whilst the combination of albumin bound paclitaxel (Abraxane) with gemcitabine extended the median OS to 8 months (16, 17) . Both these chemotherapy combinations are accepted as standard of care first-line palliative options in the advanced PDAC disease setting, but only offer limited benefit.
Regardless of these treatments and the choice of first-line chemotherapy, the overall 5-year survival rate for pancreatic cancer is less than 5% (4). Sadly, disease progression for pancreatic cancer patients with locally advanced or metastatic disease is inevitable.
There is a clear need to step outside the current treatment paradigm and investigate new diagnostic, monitoring and therapeutic opportunities to improve outcomes for this devastating disease, in both early and late stage pancreatic cancer. The results to date in early phase clinical trials of novel targeted agents in unselected chemo-refractory pancreatic cancer have fallen short of the anticipated efficacy, highlighting the lack of a reliable validated predictive or prognostic biomarker in pancreatic cancer that can inform and guide treatment decisions. A more selective approach by identifying and utilizing biomarkers that characterize patients could enable greater benefit from current and novel therapies.
Immune biomarkers in PDAC
Characterization of immune cells within the tumor microenvironment was first described by Virchow in 1863, since then work to immune-phenotype the TME of solid tumors has progressed using immune cell specific antibodies, multiplex immunohistochemistry and most recently spatial transcriptomics.
There are limited published reports on the presence of tumor infiltrating lymphocytes (TILs) assessed on H&E sections in PDAC. One study by Hart et al examined H&E sections from 63 PDAC patients, and reported no difference in survival outcomes between patients with a high versus a low intra-tumoral lymphocyte score (18) ]. In comparison, the presence of intra-tumoural tertiary lymphoid organs/ follicles is associated with longer DFS and OS (19) .
A range of immune cell markers have been investigated in PDAC with good prognostic associations found for higher expression of CD3, CD4, CD8, and CD20 (20, 21) . In comparison, higher expression of FOXP3, CD66b, CD68, CD163, and CD204 are associated with worse outcomes (20) . Myeloid cell infiltrates appear to dominate the immune reaction in PDAC (20, 22) . Elevated levels of circulating myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs) have been reported in PDAC patients, and are associated with worse prognosis and OS (22) . Of interest are immune biomarkers that could potential be used to guide treatment choices with novel immunotherapies, as they can be monitored easily, and cheaply, by blood-based screening. To date the administration of immunotherapy in clinical trials in PDAC has yet to demonstrate substantial benefit in pancreatic cancer (25) (26) (27) . The reasons for this are incompletely understood but likely to be multifactorial. Proposed mechanisms leading to immunotherapy resistance in PDAC include a markedly immunosuppressive and "immune-privileged" tumor microenvironment (20) . As previously mentioned, contributing factors to this immune-privileged TME include the paucity of T cell infiltration into the tumor, the low mutational burden in PDAC that produces few immunogenic antigens, (9, 28) and the physical barrier created by the dense desmoplastic stroma that hinders access of therapeutic 
PDL1/PD1 interaction in Pancreatic Cancer
Programmed cell death protein-1 ligand (PDL1) and its receptor, PD1, interact to promote immune tolerance ( Figure 3 ). The blockade of the PD1/PDL1 interaction acts to increase anti-tumor immunity.
Results from trials investigating the use of PD1 therapy alone in advanced PDAC have been disappointing (38, 39) 
Stimulating the immune response in Pancreatic Cancer
Therapeutic vaccine trials involving an array of recombinant constructs, peptides, proteins and whole tumor cells, all designed to prime circulating tumor specific T cells and attack PDAC, so far have reported negative outcomes (39) .Despite this lack of efficacy, these studies have provided important insight into the immune response in PDAC, confirming that T cell immunity to tumor associated selfantigens can be generated and break immune tolerance in PDAC. Furthermore, studies like the phase 2b GVAX pancreas ECLIPSE study demonstrated that it was possible to induce tertiary lymphoid structures and T cell infiltration in patients (40) . It has been hypothesized that dysfunctional T cells and suboptimal antigen selection, resulted in the overall lack of long-term survival in the therapeutic vaccine trials, despite clear evidence of an immunological response in some patients (41, 42) .
Approaches that combine therapeutic vaccines with checkpoint blockade are being undertaken to investigate whether checkpoint blockade can re-invigorate vaccine-primed T cells to overcome the immunosuppressive inhibition generated by the PDAC tumor microenvironment (43) .
Novel Immune targets of interest in Pancreatic Cancer
Work by Balli et al into immune cytolytic activity stratified PDAC patients into molecular subsets. Here inflammatory status to a tumoricidal phenotype (46) .Combining CD40 agonists with nab-paclitaxel and gemcitabine further enhanced the T cell mediated tumor destruction and generated immune memory, not seen with the gemcitabine combination alone (47) .Preclinical models indicate that the combination of CD40 agonist with gemcitabine and nab-paclitaxel can sensitize PDAC to immune checkpoint blockade (48) .
Conclusion
The relationship between inflammation and PDAC is only just beginning to be appreciated. Our 
